Global Subdermal Contraceptive Implants Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Subdermal Contraceptive Implants Market Segmentation, By Type (Etonogestrel Implant, Levonorgestrel Implant, and Others), Application (Hospital, Clinic, and Research Facilities)- Industry Trends and Forecast to 2032

Subdermal Contraceptive Implants Market Size

• The global subdermal contraceptive implants market size was valued at USD 907.28 million in 2024 and is expected to reach USD 1,178.19 million by 2032, at a CAGR of 3.32% during the forecast period
• The market growth is primarily driven by rising awareness of long-acting reversible contraceptives (LARCs) and increasing government initiatives to promote family planning and reproductive health, especially in developing regions
• In addition, the high efficacy, convenience, and extended protection offered by subdermal implants are making them a preferred choice over traditional contraceptive methods. These factors are contributing to the widespread adoption and expansion of the subdermal contraceptive implants market globally

Subdermal Contraceptive Implants Market Analysis

• Subdermal contraceptive implants, which provide long-acting reversible contraception through a small rod inserted under the skin, are becoming increasingly important in reproductive health management due to their high efficacy, low maintenance, and extended duration of action
• The growing preference for reliable and discreet birth control options, along with increased awareness and supportive governmental and NGO-led family planning initiatives, is fueling demand for subdermal implants, particularly in low- and middle-income countries
• North America dominated the subdermal contraceptive implants market with the largest revenue share of 37.3% in 2024, characterized by favorable healthcare reimbursement policies, robust healthcare infrastructure, and growing patient preference for long-term contraceptive methods
• Asia-Pacific is expected to be the fastest growing region in the subdermal contraceptive implants market during the forecast period due to expanding public health programs, rising population, and increasing acceptance of modern contraceptives in countries such as India, China, and Indonesia
• Etonogestrel implant segment dominated the subdermal contraceptive implants market with a market share of 59.2% in 2024, driven by its proven safety profile, long-term protection (up to three years), and widespread availability under brands such as Nexplanon and Implanon

Report Scope and Subdermal Contraceptive Implants Market Segmentation

Subdermal Contraceptive Implants Market Trends

“Advancing Access Through Innovation and Long-Acting Reversible Contraceptive (LARC) Integration”

• A key and accelerating trend in the global subdermal contraceptive implants market is the growing focus on improving access, effectiveness, and convenience through innovations in long-acting reversible contraceptive (LARC) delivery methods and implant design. These advancements are reshaping reproductive health strategies worldwide, especially in underserved regions

  • For instance, newer-generation implants such as Nexplanon offer enhanced insertion techniques, radiopaque visibility for easier detection, and consistent hormone release over extended periods, improving both user compliance and provider confidence. Innovations such as preloaded applicators and thinner, more flexible rods are being introduced to improve insertion ease and patient comfort

• Healthcare providers and governments are increasingly integrating subdermal implants into national family planning programs due to their cost-effectiveness, reduced user dependency, and extended protection of up to three to five years. Organizations such as UNFPA and USAID have expanded access to implants through bulk purchasing and local distribution, particularly in Sub-Saharan Africa and South Asia
• Rising use of mobile health (mHealth) platforms and community-based distribution models is also enhancing access to implant services, especially in remote or rural settings. These platforms enable appointment tracking, follow-up reminders, and educational outreach, increasing awareness and long-term usage
• The global trend toward reproductive autonomy is prompting manufacturers and NGOs to focus on user-centered contraceptive design—leading to development of customizable options and minimal side effect profiles to enhance acceptability
• As women across both developed and developing countries increasingly seek reliable, maintenance-free contraceptive options, the demand for subdermal implants with enhanced comfort, accessibility, and safety features is driving continuous market expansion

Subdermal Contraceptive Implants Market Dynamics

Driver

“Increasing Demand Driven by Long-Term Efficacy and Family Planning Initiatives”

• The rising global emphasis on effective, long-acting contraceptive methods, combined with expanding family planning initiatives, is a key driver accelerating the demand for subdermal contraceptive implants

  • For instance, in March 2024, the Bill & Melinda Gates Foundation and UNFPA jointly expanded their support for implant access in Sub-Saharan Africa and Southeast Asia, including the distribution of low-cost implants and provider training programs. Such collaborative global efforts are expected to significantly boost implant adoption in the forecast period

• Subdermal implants offer several advantages over short-term methods, including high efficacy (over 99%), minimal maintenance, and extended protection for up to 3–5 years, making them ideal for women seeking reliable, discreet birth control
• Moreover, healthcare organizations and governments are increasingly promoting implants as part of reproductive health strategies to reduce unintended pregnancies and enhance maternal health outcomes
• Rising awareness, growing acceptance of long-acting reversible contraceptives (LARCs), and inclusion of implants in subsidized public health programs are strengthening market growth, especially in emerging economies
• In addition, improved training for healthcare providers and streamlined insertion techniques have made implants more accessible and acceptable, contributing to rising demand across both rural and urban populations

Restraint/Challenge

“Skin Reactions and Stringent Regulatory Approval Processes”

• Skin irritation, localized pain, and other minor side effects at the implant site remain a notable restraint impacting user acceptance and satisfaction with subdermal contraceptive implants. While generally safe, these adverse reactions can discourage repeat usage and negatively affect perception, especially among first-time users

  • For instance, clinical reports have indicated occasional cases of redness, bruising, or swelling post-insertion, and in rare situations, complications requiring implant removal. These issues necessitate trained healthcare professionals for proper insertion and removal, adding to procedural complexity

• In addition, the stringent regulatory pathways for approval of contraceptive implants—especially in markets such as the U.S. and EU—pose a barrier for new entrants and product innovation. Companies must meet rigorous safety, efficacy, and quality standards before launching products, which can delay time to market and escalate development costs
• Regulatory compliance requirements for post-marketing surveillance and pharmacovigilance are also resource-intensive, particularly for smaller players or NGOs operating in low-resource settings
• Further complicating adoption, cultural resistance to contraceptive use in certain regions, along with misinformation or lack of education, can hinder outreach efforts despite clinical effectiveness
• Addressing these challenges through better user education, improvements in implant materials to reduce irritation, and streamlining regulatory pathways for high-need markets will be essential to overcoming these market restraints and expanding global access

Subdermal Contraceptive Implants Market Scope

The market is segmented on the basis of type and application.

• By Type

On the basis of type, the global subdermal contraceptive implants market is segmented into etonogestrel implants, levonorgestrel implants, and others. The etonogestrel implant segment held the largest market revenue share of 59.2% in 2024, attributed to its long-standing clinical acceptance, proven efficacy for up to three years, and widespread usage under brand names such as Nexplanon and Implanon. This type benefits from strong healthcare provider familiarity, FDA approval, and radiopaque properties that assist in accurate placement and removal

The levonorgestrel implant segment is projected to witness the fastest growth rate from 2025 to 2032, driven by increasing governmental and NGO-backed efforts to expand access in emerging markets. These implants, often available at lower costs through bulk procurement programs, are gaining traction due to their effectiveness for up to five years and compatibility with public health strategies aimed at reducing unintended pregnancies.

• By Application

On the basis of application, the market is segmented into hospital, clinic, and research facilities. The hospital segment dominated the market in 2024 due to the presence of skilled professionals, comprehensive reproductive health services, and broader infrastructure for implant insertion and follow-up. Hospitals are often the primary access points for long-term contraceptive solutions, especially in urban areas where women seek professionally administered care.

The clinic segment is expected to register the fastest growth during the forecast period, supported by the expansion of primary care centers and family planning clinics in both developed and developing countries. Clinics offer more affordable and accessible services compared to hospitals, making them a preferred choice for rural and low-income populations.

Subdermal Contraceptive Implants Market Regional Analysis

• North America dominated the subdermal contraceptive implants market with the largest revenue share of 37.3% in 2024, driven by favorable healthcare reimbursement policies, robust healthcare infrastructure, and growing patient preference for long-term contraceptive methods
• Consumers in the region increasingly prefer reliable, low-maintenance birth control options that offer extended protection, aligning with modern lifestyle demands and family planning goals
• This widespread adoption is further supported by strong governmental support for reproductive health, accessibility of trained healthcare professionals, and continued education campaigns that promote implant usage as a safe and effective contraceptive method, particularly among younger women and first-time users

U.S. Subdermal Contraceptive Implants Market Insight

The U.S. subdermal contraceptive implants market held the largest revenue share of 79% in North America in 2024, supported by high awareness of long-acting reversible contraceptives (LARCs), widespread insurance coverage, and strong provider networks. Growing preference for low-maintenance and highly effective birth control methods is propelling implant use, especially among younger women. In addition, continuous FDA-approved innovation, such as radiopaque implants and simplified insertion systems, is enhancing provider confidence and patient compliance across clinical settings.

Europe Subdermal Contraceptive Implants Market Insight

The Europe subdermal contraceptive implants market is projected to grow at a notable CAGR throughout the forecast period, driven by supportive healthcare policies and increasing focus on reproductive autonomy. National health programs in countries such as France, Sweden, and the Netherlands promote access to implants through public reimbursement schemes. The region’s emphasis on sexual health education and the rising demand for discreet, long-acting contraceptive options is also contributing to the increased adoption of implants in both urban and rural populations.

U.K. Subdermal Contraceptive Implants Market Insight

The U.K. subdermal contraceptive implants market is expected to grow steadily, bolstered by the NHS’s wide availability of free contraceptive services and strong public trust in LARC methods. Government-backed awareness campaigns and healthcare provider training have made implants a routine option in sexual health services. In addition, rising concern over teenage pregnancies and demand for reliable, long-term solutions is enhancing uptake across demographic groups, including adolescents and first-time users.

Germany Subdermal Contraceptive Implants Market Insight

The Germany’s subdermal contraceptive implants market is poised for steady growth, fueled by increasing demand for patient-controlled, non-daily contraceptive options. Germany’s healthcare infrastructure supports access through gynecological services and insurance reimbursement for younger women. The market is also benefiting from a cultural shift toward hormonal contraception alternatives and growing patient awareness of implant benefits such as long-term efficacy and minimal user intervention.

Asia-Pacific Subdermal Contraceptive Implants Market Insight

The Asia-Pacific subdermal contraceptive implants market is projected to grow at the fastest CAGR from 2025 to 2032, driven by high birth rates, growing demand for family planning, and expanding government support for LARC distribution. Countries such as India, Indonesia, and the Philippines are scaling up access through public health missions and donor-funded programs. Increasing female literacy and healthcare accessibility are also supporting higher implant usage across both rural and urban regions.

Japan Subdermal Contraceptive Implants Market Insight

The Japan’s subdermal contraceptive implants market is witnessing gradual growth as societal attitudes shift toward long-term contraceptive solutions. While traditionally reliant on barrier methods, growing awareness of LARCs, an aging population, and the convenience of implant use are encouraging broader acceptance. Private gynecological clinics are increasingly offering implants, supported by rising patient demand for discreet and maintenance-free options.  

India Subdermal Contraceptive Implants Market Insight

The India subdermal contraceptive implants market accounted for the largest revenue share in the Asia-Pacific subdermal contraceptive implants market in 2024, driven by a large reproductive-age population, increasing awareness of birth control, and the government’s efforts to promote LARCs under national family welfare programs. Public-private partnerships and NGO interventions are improving access in underserved regions. In addition, the availability of cost-effective implants and growing training for rural healthcare workers are accelerating adoption in community health centers and mobile clinics.

Subdermal Contraceptive Implants Market Share

The subdermal contraceptive implants industry is primarily led by well-established companies, including:

• Bayer AG (Germany)
• Organon & Co. (U.S.)
• Merck & Co., Inc. (U.S.)
• Shanghai Dahua Pharmaceutical Co., Ltd. (China)
• Gedeon Richter Plc. (Hungary)
• Mochida Pharmaceutical Co., Ltd. (Japan)
• Pfizer Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Zhejiang Xianju Pharmaceutical Co., Ltd. (China)
• HLL Lifecare Limited (India)
• Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
• Sino-Pharm International Corporation (China)
• Cipla Limited (India)
• Famy Care Ltd. (India)
• Lupin Pharmaceuticals, Inc. (India)
• Cadila Pharmaceuticals Ltd. (India)
• Afaxys, Inc. (U.S.)
• Gynopharma B.V. (Netherlands)
• DKT International (U.S.)

What are the Recent Developments in Global Subdermal Contraceptive Implants Market?

• In March 2024, the Bill & Melinda Gates Foundation, in collaboration with UNFPA and PATH, expanded its initiative to improve access to contraceptive implants in Sub-Saharan Africa by funding the distribution of low-cost, quality-assured etonogestrel and levonorgestrel implants. The program aims to increase accessibility for women in underserved regions, reduce supply chain gaps, and support local healthcare worker training. This effort underscores a global commitment to reducing unintended pregnancies through widespread LARC adoption
• In February 2024, Bayer AG announced the successful Phase III clinical trial results of its next-generation levonorgestrel-based subdermal implant designed to offer extended protection up to six years. This marks a significant advancement in implant technology, with the potential to reduce the frequency of reinsertion and improve patient adherence. Bayer’s continued R&D investment reflects its strategic focus on innovation in women’s health and long-acting contraceptive solutions
• In January 2024, Shanghai Dahua Pharmaceutical Co., Ltd. received regulatory approval from China’s National Medical Products Administration (NMPA) for its new two-rod contraceptive implant designed for local and regional use. The approval is expected to boost domestic production and availability of implants in the rapidly expanding Chinese contraceptive market, which is increasingly turning toward LARC methods for population and reproductive health management
• In November 2023, the World Health Organization (WHO), together with Jhpiego and local governments, launched a training and capacity-building program across Southeast Asia to equip primary healthcare providers with implant insertion and removal skills. The initiative aims to strengthen healthcare systems by ensuring safe, effective, and high-quality LARC services across rural and low-resource settings, emphasizing WHO’s commitment to advancing equitable access to reproductive health tools
• In October 2023, Organon & Co. expanded its strategic partnership with local health ministries in Latin America to distribute its branded etonogestrel implant through public health channels. This expansion is focused on addressing unmet contraceptive needs, particularly among adolescents and rural populations. Organon’s initiative also includes education campaigns and healthcare provider support to improve awareness and correct usage of subdermal implants

SKU-52283